Using pharmacist-directed service improves quality of care for patients

Feb 08, 2011

DETROIT ¬– A Henry Ford Hospital study has found that a pharmacist-directed anticoagulation service improves the way medication is managed for patients with heparin-induced thrombocytopenia (HIT), a common but life-threatening thromboembolic disorder.

Researchers found that treated by the anticoagulation service had a favorable response to alternative anticoagulant drugs three times faster and were 32 percent more likely to receive proper dosage than patients who were treated with the same drugs by the patient's primary medical team.

This is the first time researchers evaluated the impact of the anticoagulation service on the efficiency and safety of using a different class of anticoagulant drugs called direct thrombin inhibitors for treating patients with HIT, in which a patient's platelet count drops after they receive the anticoagulant drug heparin.

The study is to be published online Tuesday at www.theannals.com in the February issue of The Annals of Pharmacotherapy.

"Based on our findings, we believe this type of service is a valuable strategy for improving the quality of care of patients with HIT," says James Kalus, PharmD, senior clinical pharmacy manager at Henry Ford and senior author of the study.

It is estimated that up to 3 percent of patients exposed to various forms of heparin may develop HIT, which is commonly treated in hospitalized patients. If a decrease in a patient's platelet count is not treated quickly and efficiently, serious blood clots can develop.

Henry Ford sought to evaluate whether a pharmacist-directed anticoagulation service could impact the care or outcomes of 193 HIT patients who were treated using direct thrombin inhibitors lepirudin or argatroban between 2005 and 2009. Ninety-eight patients were managed by the anticoagulation service and 95 patients were managed by the primary medical team.

Dr. Kalus says the study's findings "represent real improvements in quality of care."

"The pharmacist-directed anticoagulation service is a viable approach to standardize the use of direct thrombin inhibitors for improving both the efficiency and safety of these complicated medications in an inpatient setting," he says.

Explore further: WHO: Millions of Ebola vaccine doses ready in 2015

add to favorites email to friend print save as pdf

Related Stories

Vancomycin is the drug of choice for treating cellulitis

Oct 23, 2010

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, ...

Belt and braces approach may prevent deep vein thromboses

Oct 08, 2008

Combining short periods of leg compression with medications such as heparin is more effective at preventing blood clots in high-risk patients than using either preventative measure alone. A team of Cochrane Researchers believe ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0